IP Library › Granted Patent US 12,643,939

Granted Patent B2

US 12,643,939 · App. 16/638,125 · Granted Jun 2, 2026

Antibody to Epstein Barr virus and uses thereof

Inventors: Rajiv Khanna (Herston, AU); Kristine Hua (Herston, AU)

Assignee: The Council of the Queensland Institute of Medical Research

C07K16/085 G01N33/56994 A61K2039/505 C07K2317/24 C07K2317/56 C07K2317/76 C07K2317/92 G01N2333/05 G01N2500/10

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,643,939
App. No.: 16/638,125
Granted: Jun 2, 2026
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

A recombinant, humanized antibody or antibody fragment that is capable of at least partly preventing or inhibiting Epstein Barr Virus gp350 binding to a human cell. The antibody may be useful for passively immunizing humans against Epstein Barr Virus and/or treating or preventing Epstein Barr Virus-associated diseases, disorders or conditions. The antibody or antibody fragment may also be used to detect Epstein Barr Virus.

Claims (283)

1 . A recombinant, human or humanized antibody or antibody fragment that is capable of at least partly reducing or inhibiting Epstein Barr Virus (EBV) gp350 binding to a human cell, which comprises six complementarity determining regions (CDR)s comprising a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 selected from:

Clone

CDR

SEQ ID NO:

HCDR1

1 (Chothia), 37 (AbM), 73

(Kabat), 109

HCDR2

2 (Chothia), 38 (AbM), 74

(Kabat), 110

HCDR3

3 (Chothia), 39 (AbM), 75

(Kabat), 111

LCDR1

19 (Chothia), 55 (AbM), 91

(Kabat), 127

LCDR2

20 (Chothia), 56 (AbM), 92

(Kabat), 128

LCDR3

21 (Chothia), 57 (AbM), 93

(Kabat), 129; or

A11

HCDR1

4 (Chothia), 40 (AbM), 76

(Kabat), 112

HCDR2

5 (Chothia), 41 (AbM), 77

(Kabat), 113

HCDR3

6 (Chothia), 42 (AbM), 78

(Kabat), 114

LCDR1

22 (Chothia), 58 (AbM), 94

(Kabat), 130

LCDR2

23 (Chothia), 59 (AbM), 95

(Kabat), 131

LCDR3

24 (Chothia), 60 (AbM), 96

(Kabat), 132 (Contact)

E10

HCDR1

7 (Chothia), 43 (AbM), 79

(Kabat), 115 (Contact)

HCDR2

8 (Chothia), 44 (AbM), 80

(Kabat), 116 (Contact)

HCDR3

9 (Chothia), 45 (AbM), 81

(Kabat), 117 (Contact)

LCDR1

25 (Chothia), 61 (AbM), 97

(Kabat), 133 (Contact)

LCDR2

26 (Chothia), 62 (AbM), 98

(Kabat), 134 (Contact)

LCDR3

27 (Chothia), 63 (AbM), 99

(Kabat), 135 (Contact)

HCDR1

10 (Chothia), 46 (AbM), 82

(Kabat), 118 (Contact)

HCDR2

11 (Chothia), 47 (AbM), 83

(Kabat), 119 (Contact)

HCDR3

12 (Chothia), 48 (AbM), 84

(Kabat), 120 (Contact)

LCDR1

28 (Chothia), 64 (AbM), 100

(Kabat), 136 (Contact)

LCDR2

29 (Chothia), 65 (AbM), 101

(Kabat), 137 (Contact)

LCDR3

30 (Chothia), 66 (AbM), 102

(Kabat), 138 (Contact)

HCDR1

13 (Chothia), 49 (AbM), 85

(Kabat), 121 (Contact)

HCDR2

14 (Chothia), 50 (AbM), 86

(Kabat), 122 (Contact)

HCDR3

15 (Chothia), 51 (AbM), 87

(Kabat), 123 (Contact)

LCDR1

31 (Chothia), 67 (AbM), 103

(Kabat), 139 (Contact)

LCDR2

32 (Chothia), 68 (AbM), 104

(Kabat), 140 (Contact)

LCDR3

33 (Chothia), 69 (AbM), 105

(Kabat), 141 (Contact)

C10

HCDR1

16 (Chothia), 52 (AbM), 88

(Kabat), 124 (Contact)

HCDR2

17 (Chothia), 53 (AbM), 89

(Kabat), 125 (Contact)

HCDR3

18 (Chothia), 54 (AbM), 90

(Kabat), 126 (Contact)

LCDR1

34 (Chothia), 70 (AbM), 106

(Kabat), 142 (Contact)

LCDR2

35 (Chothia), 71 (AbM), 107

(Kabat), 143 (Contact)

LCDR3

36 (Chothia), 72 (AbM), 108,

144 (Contact).

2 . The recombinant human or humanized antibody or antibody fragment of claim 1 , produced by phage display wherein the phage comprise one or more nucleotide sequences of human origin encoding one or more amino acid sequence of the human or humanized antibody or antibody fragment.

3 . The recombinant human or humanized antibody or antibody fragment of claim 1 , which comprises, consists essentially of or consists of an amino acid sequence set forth in any one of SEQ ID NOS: 145-156, or an amino acid sequence at least 90% identical thereto.

4 . The recombinant, human or humanized antibody or antibody fragment of claim 1 , further comprising a human IgG1 constant region amino acid sequence.

5 . An antibody or antibody fragment comprising a heavy chain (VH) variable region sequence and a light chain (VL) variable region sequence selected from:

Clone

Chain

SEQ ID NO:

145

151

A11

146

152

E10

147

153

148

154

149

155

C10

150

156

wherein the VH variable region sequence according to any one of SEQ ID NOs: 145-150 has an amino acid sequence at least 90% identical thereto, and wherein the light chain (VL) variable region sequence according to any one of SEQ ID NOS: 151-156 or an amino acid sequence at least 90% identical thereto; wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 animo acid sequences are selected from:

Clone

CDR

SEQ ID NO:

HCDR1

1 (Chothia), 37 (AbM), 73

(Kabat), 109

HCDR2

2 (Chothia), 38 (AbM), 74

(Kabat), 110

HCDR3

3 (Chothia), 39 (AbM), 75

(Kabat), 111

LCDR1

19 (Chothia), 55 (AbM), 91

(Kabat), 127

LCDR2

20 (Chothia), 56 (AbM), 92

(Kabat), 128

LCDR3

21 (Chothia), 57 (AbM), 93

(Kabat), 129; or

A11

HCDR1

4 (Chothia), 40 (AbM), 76

(Kabat), 112

HCDR2

5 (Chothia), 41 (AbM), 77

(Kabat), 113

HCDR3

6 (Chothia), 42 (AbM), 78

(Kabat), 114

LCDR1

22 (Chothia), 58 (AbM), 94

(Kabat), 130

LCDR2

23 (Chothia), 59 (AbM), 95

(Kabat), 131

LCDR3

24 (Chothia), 60 (AbM), 96

(Kabat), 132 (Contact)

E10

HCDR1

7 (Chothia), 43 (AbM), 79

(Kabat), 115 (Contact)

HCDR2

8 (Chothia), 44 (AbM), 80

(Kabat), 116 (Contact)

HCDR3

9 (Chothia), 45 (AbM), 81

(Kabat), 117 (Contact)

LCDR1

25 (Chothia), 61 (AbM), 97

(Kabat), 133 (Contact)

LCDR2

26 (Chothia), 62 (AbM), 98

(Kabat), 134 (Contact)

LCDR3

27 (Chothia), 63 (AbM), 99

(Kabat), 135 (Contact)

HCDR1

10 (Chothia), 46 (AbM), 82

(Kabat), 118 (Contact)

HCDR2

11 (Chothia), 47 (AbM), 83

(Kabat), 119 (Contact)

HCDR3

12 (Chothia), 48 (AbM), 84

(Kabat), 120 (Contact)

LCDR1

28 (Chothia), 64 (AbM), 100

(Kabat), 136 (Contact)

LCDR2

29 (Chothia), 65 (AbM), 101

(Kabat), 137 (Contact)

LCDR3

30 (Chothia), 66 (AbM), 102

(Kabat), 138 (Contact)

HCDR1

13 (Chothia), 49 (AbM), 85

(Kabat), 121 (Contact)

HCDR2

14 (Chothia), 50 (AbM), 86

(Kabat), 122 (Contact)

HCDR3

15 (Chothia), 51 (AbM), 87

(Kabat), 123 (Contact)

LCDR1

31 (Chothia), 67 (AbM), 103

(Kabat), 139 (Contact)

LCDR2

32 (Chothia), 68 (AbM), 104

(Kabat), 140 (Contact)

LCDR3

33 (Chothia), 69 (AbM), 105

(Kabat), 141 (Contact)

C10

HCDR1

16 (Chothia), 52 (AbM), 88

(Kabat), 124 (Contact)

HCDR2

17 (Chothia), 53 (AbM), 89

(Kabat), 125 (Contact)

HCDR3

18 (Chothia), 54 (AbM), 90

(Kabat), 126 (Contact)

LCDR1

34 (Chothia), 70 (AbM), 106

(Kabat), 142 (Contact)

LCDR2

35 (Chothia), 71 (AbM), 107

(Kabat), 143 (Contact)

LCDR3

36 (Chothia), 72 (AbM), 108,

144 (Contact).

6 . The antibody or antibody fragment of claim 5 , wherein the VH sequence consists essentially of or consists of an amino acid sequence set forth in any one of SEQ ID NOS: 145-150, and the VL sequence consists essentially of or consists of an amino acid sequence set forth in any one of SEQ ID NOS: 151-156.

7 . The antibody or antibody fragment of claim 5 , produced by phage display wherein the phage comprise one or more nucleotide sequences of human origin encoding one or more amino acid sequences of the human or humanized antibody or antibody fragment.

8 . The antibody or antibody fragment according to claim 5 , which is capable of at least partly preventing or inhibiting EBV gp350 binding to a human cell.

9 . An isolated nucleic acid encoding a recombinant, human or humanized antibody or antibody fragment according to claim 1 .

10 . A genetic construct comprising the isolated nucleic acid of claim 9 .

11 . A host cell comprising the genetic construct of claim 10 .

12 . A composition comprising a recombinant, human or humanized antibody or antibody fragment according to claim 1 , and a pharmaceutically acceptable carrier diluent or excipient.

13 . A method of treating an EBV infection in a human, said method including the step of administering a composition comprising a recombinant, human or humanized antibody or antibody fragment according to claim 1 to the human to thereby treat an EBV infection in the human.

14 . A method of at least partly inhibiting EBV gp350 binding to a human cell, said method including the step of administering a recombinant, human humanized antibody or antibody fragment according to claim 1 to the human to thereby at least partly inhibit EBV gp350 binding to a human cell.

15 . A method of detecting EBVgp350 or a cell expressing EBVgp350, said method including the step of forming a complex between a recombinant, human or humanized antibody or antibody fragment according to claim 1 and EBV gp350 to thereby detect EBVgp350 or the cell expressing EBVgp350, wherein the antibody or antibody fragment is labeled.

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2021

From: KHANNA, RAJIV; HUA, KRISTINE

To: THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH

Reel/Frame 056509/0285 →

Priority Claims (1)

AU 2017903197 · Aug 10, 2017 · national

Continuity (1)

Related Publication 20200255499A1 · Aug 13, 2020

References Cited (22)

US 6180370B1 · Queen · 2001 [cited by examiner]

US 9376485B2 · Wang · 2016 [cited by examiner]

WO WO2013130565A1 · 2013 [cited by examiner]

WO WO2015117244A1 · 2015 [cited by applicant]

Stryer, Biochemistry 4th, WH Freeman, New York. 1995 (Year: 1995). [cited by examiner]

Colman, Peter M. Research in Immunology 145.1 (1994): 33-36 (Year: 1994). [cited by examiner]

Haque, Tanzina, et al. “A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo.” The Journal of infectious diseases 194.5 (2006): 584-587. (Year: 20… [cited by examiner]

Islas-Ohlmayer, Miguel et al. “Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.” Journal of virology vol. 78,24 (2004): 13891-900. doi:10.1128/JVI.78.24.13891-13900.2… [cited by examiner]

Kleiveland CR. Peripheral Blood Mononuclear Cells. In: Verhoeckx K, Cotter P, López-Expósito I, et al., editors. The Impact of Food Bioactives on Health: in vitro and ex vivo models [Internet]. Cham (CH): Springer; 2015… [cited by examiner]

Kipriyanov, Sergey M., and Fabrice Le Gall. “Generation and production of engineered antibodies.” Molecular biotechnology 26.1 (2004): 39-60. (Year: 2004). [cited by examiner]

Janeway, Charles A. “Immunobiology: The Immune System in Health and Disease.” 2001 (Year: 2001). [cited by examiner]

Haque, T. et al., “A Mouse Monoclonal Antibody against Epstein-Barr Virus Envelope Glycoprotein 350 Prevents Infection Both In Vitro and In Vivo,” Journal of Infectious Diseases, vol. 194; 584-587 (2006). [cited by applicant]

Notification of Transmittal of the International Search Report and the Written Opinion for International Application No. PCT/AU2018/050851, titled: “Antibody to Epstein Barr Virus and Uses Thereof,” mailed: Oct. 31, 201… [cited by applicant]

Notification of Transmittal of International Preliminary Report on Patentability for International Application No. PCT/AU2018/050851, titled: “Antibody to Epstein Barr Virus and Uses Thereof,” mailed: Dec. 5, 2019. [cited by applicant]

Coghill, A. E. and A. Hildesheim, “Epstein-Barr Virus Antibodies and the Risk of Associated Malignancies: Review of the Literature.” American Journal of Epidemiology, vol. 180; No. 7; 687-695 (2014). [cited by applicant]

Gu, S. Y. et al., “First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen.” Dev Biol Stand, vol. 84; 171-177 (1995). (Abstract Only). [cited by applicant]

Moutschen, M. et al., “Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults.” Vaccine, vol. 25; No. 24; 4697-4705 (2007). [cited by applicant]

Sashihara, J. et al., “Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge.” PLoS Pathog, vol. 7; No. 10; c1002308 (2011). [cited by applicant]

Szakonyi, G. et al., “Structure of the Epstein-Barr virus major envelope glycoprotein.” Nat Struct Mol Biol, vol. 13; No. 11; 996-1001 (2006). [cited by applicant]

Tanner, J.E. et al., “Peptides Designed to Spatially Depict the Epstein-Barr Virus Major Virion Glycoprotein gp350 Neutralization Epitope Elicit Antibodies That Block Virus-Neutralizing Antibody 72A1 Interaction with th… [cited by applicant]

Weiss, E.R. et al., “High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis,” Journal of Virology, vol. 91; I… [cited by applicant]

Communication pursuant to Rule 164(1) EPC, Partial European Search Report for EP Application No. 18844134.9, titled: “Antibody to Epstein Barr Virus and Uses Thereof,” mailed Mar. 31, 2021. [cited by applicant]